Company Filing History:
Years Active: 2009
Title: Inventor Profile: Esther Regina De Rooij
Introduction
Esther Regina De Rooij is a notable inventor based in Eemnes, Netherlands. With a strong focus on biotechnology, she has made significant contributions to the field, particularly through her innovative approaches to nucleic acid detection. Her work has the potential to greatly enhance diagnostic capabilities in various healthcare settings.
Latest Patents
Esther's patent, titled "Storing and Detecting Nucleic Acid Administered to a Solid Carrier," outlines a method for detecting nucleic acids in samples. This invention presents a systematic approach for stabilizing body fluid samples, allowing them to be securely shipped from a collection site to testing laboratories worldwide. The method involves administering a specified volume of sample to a solid carrier that can absorb the sample, followed by a drying process and extraction of nucleic acids using a nucleic acid isolation solution. Additionally, the invention describes a kit designed for detecting, identifying, and quantifying nucleic acids in samples, streamlining procedures in laboratories, especially in less-developed countries.
Career Highlights
Esther is affiliated with Primagen Holding B.V., a company focused on developing innovative diagnostic technologies. Her contributions to the field are underscored by her strong technical expertise and her commitment to improving medical testing methods.
Collaborations
In her professional journey, Esther collaborates with colleagues like Marinus Petrus De Baar. Their teamwork exemplifies the collaborative efforts in advancing medical diagnostics and reflects the importance of partnerships in innovating new technologies.
Conclusion
Esther Regina De Rooij's work marks a significant milestone in the realm of nucleic acid detection and sample stabilization. Her patent exemplifies the intersection of innovation and practical application, reinforcing the critical role of inventors in shaping the future of healthcare diagnostics.